Maaß, Henrike
Ynga-Durand, Mario
Milošević, Marko
Krstanović, Fran
Matešić, Marina Pribanić
Žuža, Iva
Jonjić, Stipan
Brizić, Ilija
Šustić, Alan
Bloos, Frank
,
Marx, Gernot
Jaschinski, Ulrich
Reinhart, Konrad
Spies, Claudia
Reil, Lorenz
Putensen, Christian
Ragaller, Maximilian
Utzlino, Stefan
Mörer, Onnen
Gründling, Matthias
Kluge, Stefan
Nierhaus, Axel
Welte, Tobias
Bauer, Michael
Bloos, Frank
Ludwig, Katrin
Kiehntopf, Michael
Elke, Gunnar
Bogatsch, Holger
Engel, Christoph
Loeffler, Markus
Briegel, Josef
Kaufmann, Ines
John, Stefan
Riessen, Reimer
Meybohm, Patrick
Protić, Alen
Čičin-Šain, Luka
Funding for this research was provided by:
RESIST Excellence cluster (EXC 2155, project B6, EXC 2155, project B6)
Croatian Science Foundation (IP-CORONA-04-2073)
Helmholtz Association’s Initiative and Networking Fund (KA1-Co-02 “COVIPA”)
Helmholtz Association EU partnering grant (PIE-0008)
Helmholtz-Zentrum für Infektionsforschung GmbH (HZI)
Article History
Received: 10 October 2023
Accepted: 7 June 2024
First Online: 13 June 2024
Competing interests
: LCS received consulting fees by CORAT Therapeutics, DIGID Diagnostics, Dr. Wolff Group and SANOFI Pharma. LCS received speaker’s honoraria by SWIXX Pharma and SANOFI Pharma. LCS has the following patents: EP3655526 and EP22153256.7. LCS has unpaid positions in the HZI Board of Trustees, he is a member of the Vaccine task force of the European Federation of Immunological Societies and is the co-coordinator for the Vaccine group of the German Immunological Society. Other authors have no competing interest.